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Abstract
O
6-methylguanine DNA-methyltransferase (MGMT) promoter methylation has been identified as a potential prognostic
marker for glioblastoma patients. The relationship between the exact site of promoter methylation and its effect on gene
silencing, and the patient’s subsequent response to therapy, is still being defined. The aim of this study was to
comprehensively characterize cytosine-guanine (CpG) dinucleotide methylation across the entire MGMT promoter and to
correlate individual CpG site methylation patterns to mRNA expression, protein expression, and progression-free survival. To
best identify the specific MGMT promoter region most predictive of gene silencing and response to therapy, we determined
the methylation status of all 97 CpG sites in the MGMT promoter in tumor samples from 70 GBM patients using quantitative
bisulfite sequencing. We next identified the CpG site specific and regional methylation patterns most predictive of gene
silencing and improved progression-free survival. Using this data, we propose a new classification scheme utilizing
methylation data from across the entire promoter and show that an analysis based on this approach, which we call 3R
classification, is predictive of progression-free survival (HR =5.23, 95% CI [2.089–13.097], p,0.0001). To adapt this approach
to the clinical setting, we used a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) test
based on the 3R classification and show that this test is both feasible in the clinical setting and predictive of progression free
survival (HR =3.076, 95% CI [1.301–7.27], p=0.007). We discuss the potential advantages of a test based on this promoter-
wide analysis and compare it to the commonly used methylation-specific PCR test. Further prospective validation of these
two methods in a large independent patient cohort will be needed to confirm the added value of promoter wide analysis of
MGMT methylation in the clinical setting.
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Introduction
The current standard of care for patients diagnosed with
glioblastoma multiforme (GBM) has evolved to include surgery with
maximum feasible resection [1], radiotherapy [2] with concomitant
temozolomide chemotherapy, followed by adjuvant temozolomide
chemotherapy [3]. The addition of temozolomide (TMZ) improved
overall and progression-free survival [3], but despite this advance,
70% of patients still experience disease progression within one year
[3]. Response to TMZ has been shown to be heterogeneous and
debate remains as to the dose and frequency of TMZ administration
both in the general patient population as well as in individual patients
[4]. Clinical approaches designed to optimize temozolomide
effectiveness in individual patients may present an opportunity to
extend survival even further [5].
TMZ damages DNA by introducing alkyl groups at multiple
sites along the DNA backbone, impairing DNA replication, and
triggering cell death. The alkylation of the O
6 position of guanine
is a particularly cytotoxic lesion. Normal cells contain DNA repair
proteins that remove these alkyl groups or alkylated nucleotides
allowing for normal DNA replication. One of the DNA-repair
proteins, O
6-alkylguanine DNA alkyltransferase (AGT), removes
alkyl adducts from the O
6 position of guanine and the O
4 position
of thymine, effectively restoring these DNA bases and preventing
TMZ-induced cell death. The DNA-repair protein AGT is
encoded by the gene O
6-Methlyguanine-DNA-methyltransferase
(MGMT). Tumor cells expressing this gene have been shown to be
resistant to alkylating agents, while those that lack the DNA-repair
protein appear to be more susceptible [6]. In most cases, the
silencing of MGMT is associated with methylation of cytosine
nucleotides at cytosine-guanine dinucleotides (CpG sites) present
in the gene’s promoter region.
Although MGMT methylation status appears to be a predictive
marker of response to TMZ in patients with newly diagnosed
GBM [7], there have been several issues which have prevented
widespread adoption of this marker in clinical practice. First,
definitive confirmation of the predictive value of MGMT
methylation as measured by the commercially available methyl-
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awaits the results of a randomized prospective trial [5]. Second,
current techniques available for testing MGMT methylation either
lack precision, as is the case with qMSP [9,10], or are too
expensive and time-consuming to be used in clinical practice [11].
Third, the MGMT promoter consists of 97 CpG sites which are
not uniformly methylated in individual patients or across a patient
population [12]. All previous studies correlating MGMT methyl-
ation status with patient response to therapy have tested only a
small segment of the downstream promoter [13] whereas
methylation of both upstream as well as downstream sites have
been shown to repress MGMT transcription [12,14]. The
predictive value of the upstream promoter region has been
suggested but not yet correlated with clinical response [12,14].
Finally, as there are no clear alternative treatments for patients
with unfavorable MGMT methylation status, testing has been
primarily limited to research trials. Once the predictive value is
confirmed and alternative treatments become available [15], it will
be important to have a high throughput, standardized diagnostic
test to assess MGMT methylation for treatment planning.
Two significant issues need to be addressed in order to optimize
MGMT methylation testing for use in clinical practice. First, the
specific MGMT promoter regions most predictive of patient response
to therapy need to be identified and validated. Second, the
heterogeneity of methylation patterns across the promoter region
and within individual tumors needs to be characterized in order to
optimize probe design for PCR-based methods. To address these
issues, we characterized MGMT promoter methylation patterns using
bisulfite sequencing to obtain quantitative methylation results for all 97
CpG sites in 70 newly diagnosed GBM patients. Using a similar
approach, Everhard et al. have previously shown a correlation between
promoter-wide methylation patterns and MGMT mRNA expression
[12]. We confirm these findings and further extend this approach to
show, for the first time, how individual CpG site-specific methylation
patterns correlate with MGMT mRNA expression, MGMT protein
immunohistochemistry (IHC), and patient response to primary
therapy. We then use statistical modeling to identify the individual
CpG sites and related MGMT promoter regions most predictive of
TMZ response. Based on this analysis, we propose a new classification
scheme that utilizes methylation data from three different regions
spanning the entire promoter and show that this approach is predictive
of clinical response. Recognizing that bisulfite sequencing is laborious
and expensive, we designed a new test utilizing methylation-specific
multiplex ligation-dependent probe amplification (MS-MLPA) of
individual CpG sites specific to each of the three promoter regions
and show that this MS-MLPA based test is both feasible in the clinical
setting and potentially more sensitive in identifying patients with
MGMT promoter methylation. These findings warrant further
prospective clinical study to validate the additional benefit of
developing an MS-MLPA based whole promoter test as an alternative
or adjunct to the commonly used qMSP test.
Materials and Methods
Ethics statement
This study was reviewed and approved by human subjects
committees at the University of Iowa IRB (IRB199812055), and
Western IRB (IRB00000533) in compliance with the ethical
principles as set forth in the report of the National Commission for
the Protection of Human Subjects of Biomedical and Behavioral
Research entitled ‘‘Ethical Principles and Guidelines for the
Protection of Human Subjects of Research (Belmont Report)’’.
The research protocol was also approved by the Swedish
Neuroscience Institute research steering committee. All partici-
pants provided written informed consent according to IRB
guidelines prior to participation in this study.
Patients and tissue collection
Patient tissue samples were obtained from two institutions, the
University of Iowa Hospital and Clinics, IA, USA (Iowa cohort)
and Swedish Medical Center, WA, USA (Swedish cohort). All
patients gave informed consent prior to collection of specimens
according to institutional guidelines. Tissue samples were snap-
frozen in the operating room immediately during surgery with an
adjacent specimen sent to pathology for diagnosis by a board-
certified neuropathologist. Each tumor specimen was archived at
280uC for further DNA, RNA and protein studies. All patients
underwent surgery for tumor resection, had post-operative
diagnosis of WHO grade IV glioblastoma multiforme (GBM),
received radiation therapy with concurrent temozolomide chemo-
therapy and subsequent temozolomide adjuvant chemotherapy.
For the Iowa cohort surgeries were performed between June 1999
to July 2008 and for the Swedish cohort surgeries were performed
during the period of February 2007 to April 2010. All clinical data
was collected prospectively according to institutional guidelines.
Progression free survival (PFS) was calculated as the number of
days between the date of surgery and the date of MRI scan that
showed disease progression or recurrence.
Bisulfite sequencing
Genomic DNA was extracted from 25 mg of frozen GBM tissue
using ChargeSwitch Genomic DNA mini tissue kit (Invitrogen,
Carlsbad,CA). Sodium bisulfite modification of 4 ug was carried
out using the MethylEasy DNA bisulfite modification kit (Human
Genetic Signatures, Sydney,Australia). The MGMT promoter
associated CpG island was identified using the UCSC genome
browser [16,17]. Two rounds of PCR were performed to get 400–
500 bp products. The PCR mixture contained 20 pmol of each
primer, 20 ng of bisulfite-treated DNA (or 2 ul of first round
product), 1.25 units of Taq DNA polymerase (5Prime), 200 mM
dNTPs and 1.5 mM Mg(OAc)2 in a final volume of 50 ul. The
PCR was performed with initial denaturing at 94uC for 3 min
followed by 40 cycles of denaturing at 94uC for 1 min, annealing
at 55uC for 2 min, extension for 3 min at 68uC, and a final
extension at 68uC for 10 min. The MGMT CpG island is 762 bp
in length. It was amplified in two parts. To amplify the region
upstream of the transcription start site, the following primer pairs
were used: for 1
st round, F- AAA ACR AAA TCT AAA ACR
AAA CRA AAC CRA AAA CCT AAA AAA AA, R- TAT TAT
AGG TTT TGG AGG TTG TTT TTA CGG TTT TTT GAT,
and for 2
nd round, F- AAA CTA AAA CRA AAC CCR AAA
AAA ACR AAA TAT TCC, R- TAG GGT TTT TGT TGG
TTT GGG GGT TTT TGA T. To amplify the downstream
region, the following primer pairs were used: for 1
st round, F-
CCA ATC CAC AAT CAC TAC AAC RCA ACC TAA TCC
AAA, R- GAA GGG TTA TTY GGG TTA GGY GTA TAG
GGT, and for 2
nd round, F- CCC AAA CCC GAA AAA AAA
CTA AAC AAC ACC TAA AAA A, R- GGY GTT TAG YGA
GGA TGY GTA GAT TGT TTT AGG TT. The PCR products
were cleaned using ChargeSwith PCR Clean-Up Kit (Invitrogen,
Carlsbad,CA) and cloned using the TOPO TA cloning kit(Invi-
trogen, Carlsbad,CA). The bacterial colonies were inoculated in
96 well plates in 2YT media with appropriate antibiotic. Plasmid
DNA were purified using Sprint Prep (Agencourt Biosciences,
Beverly,MA) on a Biomek FX(Beckman Coulter). DNA was
sequenced using Big Dye Terminator v3.1 (Applied Biosystems,
Foster City,CA) and the sequences were resolved on a 3730 XL
DNA Analyzer (Applied Biosystems). Multiple clones were
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sequence data was then assembled using the phredPhrap program
[18,19]. BiQ Analyzer software [20] was used for quality control
and for calculating fraction methylation at each CpG site.
MGMT mRNA
Total RNA was isolated from tissue samples with Triazol
(Invitrogen), and then cleaned with RNeasy MinElute Cleanup Kit
(Qiagen). 1 ug of total RNA was used to generate 100 ul of cDNA
using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). Real-time PCR of MGMT was performed
on the ABI PRISM 7900 HT detection system using a taqman
probe (Hs00172470_m1, Applied Biosystems) and taqman re-
agents under default conditions: 95uC for 10 minutes, 40 cycles of
95uC for 15 seconds, and 60uC for 1 minute with human beta-
glucuronidase (hGUS) as endogenous control. All assays were
done in triplicate. The expression level of MGMT for each tissue
sample was calculated compared to the hGUS expression level
using the formula 2
2(Ct value of MGMT – Ct value of hGUS).
MGMT IHC
Tissue sections were fixed in 10% buffered formalin and
blocked in paraffin. Sections of 6 micron thickness were incubated
with antibodies to O6-methylguanine-DNA methyltransferase
(MGMT) from Santa Cruz Biotechnology (MT 3.1/sc-56157).
Vizualization of the reaction product was accomplished using a
biotinylated secondary antibody exposed to an avidin and
biotinylated horseradish peroxidase macromolecular complex. A
representative portion of the tumor containing less than 10%
necrosis and without evidence of excessive macrophage infiltration
was chosen for MGMT IHC studies. The entire immunoslide was
reviewed along with the hematoxylin and eosin-stained slide and
the percentage of tumor nuclei positive for MGMT was
determined. GBM tissue with high MGMT protein expression
was used as a positive control. Tissue samples were also assayed
with no primary antibody as negative controls to rule out non-
specific reaction. Staining of endothelial cells was used as positive
internal control. As per Capper et al. (see Discussion section)
samples with greater than 15% positively stained nuclei were
considered immunopositive for MGMT [21].
Methylation-Specific Multiplex Ligation-Dependent
Probe Amplification (MS-MLPA)
MLPA probes containing methylation-sensitive HhaI recogni-
tion site (GCGC) were annealed to genomic regions (R1, R2, and
R3, see Figure 1) of MGMT and ligated. The ligated products
were then digested with HhaI, which cuts at unmethylated GCGC
sites. After PCR amplification with adapter primers linked to the
MLPA-probes, the methylated regions amplify and are detected
while the digested unmethylated regions fail to amplify[22]. The
SALSA MLPA KIT P200-A1 Human DNA Reference-1 ((MRC-
Holland, Amsterdam, The Netherlands) was used to perform the
MS-MLPA test. This kit contains control fragments and reference
probes. The standard protocol (MS-MLPA DNA Methylation
Quantification Protocol, MRC-Holland, Amsterdam, The Nether-
lands) was followed. For MGMT PCR, F- GGG TTC CCT AAG
GGT TGG A, R- GTG CCA GCA AGA TCC AAT CTA GA
primers were used. Three sets of primers were used for detecting
methylation at CpG site 8 (MLPA-R1), 22 (MLPA-R2) and 80
(MLPA-R3). These CpG sites were chosen based on the presence
of the methylation-sensitive HhaI recognition site. CpG 80 also
correlated well with mRNA, protein expression and PFS whereas
CpG 22 correlated well with mRNA expression and PFS (Table 2).
For MLPA-R1, F- GGG TTC CCT AAG GGT TGG ATC AGC
GTA GCC GCC CCG AGC A, R- GGA CCG GGA TTC TCA
CTA AGC GGG CGC CGT CTC TAG ATT GGA TCT TGC
TGG CAC; MLPA-R2, F- GGG TTC CCT AAG GGT TGG
AGA CCC CCG CGC GCT TTC AG, R- GAC CAC TCG
GGC ACG TGG CAG GTA ATC TAG ATT GGA TCT TGC
TGG CAC; and for MLPA-R3, F- GGG TTC CCT AAG GGT
TGG AGT CCT CGC GGT GCG CAC CGT T, R- TGC GAC
TTG GTG AGT GTC TGG GTC GCC TCG CTC CTC TAG
ATT GGA TCT TGC TGG CAC. Three replicates were
performed for each sample. Data were analyzed by the Coffalyser
software with a cut-off value of 0.3 to identify methylated samples
per the manufacturer’s recommendation (MRC-Holland). Addi-
tionally, the data were also checked by manual analysis.
Statistical analysis
Methylation profile. A methylation profile was calculated
for each of the 97 CpG sites in the MGMT promoter associated
CpG island in all 70 patient tissue samples. At each CpG site, a
fraction of methylation was calculated as the ratio of methylated
clones over the total number of clones sequenced per patient tissue
sample. A cutoff value of 0.1 was used to allow a binary
classification of each site as methylated or unmethylated[12].
Stratification of methylation patterns – 3R classifica-
tion. A data matrix of methylation profiles from all 70 patients
was used as input for the MEV software package [23]. Euclidean
distance measure and average link clustering were used to cluster all
97 CpG sites. Three CpG site clusters were identified in which at
least one CpG site significantly correlated with mRNA expression,
IHC staining, or PFS. CpG sites in each cluster were contiguously
located on the CpG island. Three regions were defined based on
these three clusters. Region 1 (R1) contains 15 CpG sites, region 2
(R2) contains 29 sites, and region 3 (R3) contains 27 sites (Figure 2).
Coordinates from the transcription start site for R1 were 2452 to
2317, for R2 were 2302 to 2105 and forR3 were +40 to +255. All
three regions of the MGMT promoter for each patient were
classified as methylated or unmethylated. The methylation status of
each region was determined based on the average methylation of
CpG sites in each region with a cutoff value of 0.1. Based on the
status of these three regions, patients were classified into four major
groups and eight subgroups: Group A - All three regions
unmethylated; Group B - one region methylated (B1=R3
methylated, B2=R2 methylated, B3=R1 methylated); Group C
- two regions methylated (C1=R2 and R3 methylated, C2= R1
and R3 methylated, C3= R1 and R2 methylated); Group D - all
regions methylated. These groups are shown in Figure 1. Overall
methylation profiles were classified as methylated or unmethylated
based on the methylation status of the three regions (3R
classification method). If two or more regions were methylated
then the profile was classified as methylated (Groups C and D). If
less than two regions were methylated then the profile was classified
as unmethylated (Groups A and B).
Correlation analysis. The correlation of individual CpG site
methylation with MGMT mRNA expression level was calculated
using Spearman’s rank correlation. Fractional methylation and
mRNA expression level were both continuous variables. Fractional
methylation of a promoter region was calculated by averaging
methylation of all CpG sites in that region. For correlation of
methylation with IHC staining, binary values were used for both
methylation, cutoff set at 0.1 [12], and IHC staining, cutoffset at 15%
[21]. Significanceof concordance between methylation and IHCwas
performed using Pearson’s chi-square test. The Kaplan–Meier
estimator and Hazards Ratio were used to compare PFS
distributions between methylated and unmethylated groups. Log
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PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e16146Figure 1. MGMT methylation profiles of 70 GBM samples show four distinct groups. Each row represents an individual patient. For each
patient the qMSP
P positive result is shown as a black rectangle. The next column shows the results of the qMSP test (Labcorp). PFS is represented by a
circle with a blackened circle representing greater than 1 year PFS. Positive MGMT protein expression (.15% tumor cells stained positive in IHC) is
shown as black rounded rectangle and negative expression is shown as white rounded rectangle. MGMT mRNA expression is shown using color-
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CpG sites were excluded as they are known to be methylated in
normal samples [12]. Wealso excluded CpG sites inthe region -99 to
21 because they are unmethylated in more than 80% of the patients
precluding the statistical power to achieve significance. The SPSS
software package (http://www.spss.com/) was used for this analysis.
Predicted Methylation-specific PCR (qMSP
P). Results of
the commercially-available qMSP test (LabCorp, USA)[8] were
only available for ten patients from the Swedish cohort. We sought
to predict qMSP results for the rest of the patients by analyzing
their bisulfite sequencing data to identify the fraction of
methylation for each of the seven CpG sites that span the qMSP
test primers. Previous studies which directly compared bisulfite
sequencing with MSP for identification of MGMT methylation
provided validation for this approach [9,24]. As seen in 1, the
forward primer of the qMSP test spans four CpG sites (forward
primer set) and the reverse primer spans three CpG sites (reverse
primer set) in region 3 of the MGMT promoter [8]. Based on
previously published studies [9,24] as well as the requirement that
each MSP primer must contain more than one CpG site to
distinguish between methylated and unmethylated DNA [25], we
conservatively estimated that at least two CpG sites from each of
the forward and reverse primer sets would need to be methylated
in order for the qMSP test to be positive for methylation. We
denote this predicted qMSP result as qMSP
P to distinguish it from
the commercially available qMSP [8]. We also validated our
results by comparing our qMSP
P to the commercially-available
qMSP on ten patient samples for which we found 100%
concordant results (1).
Results
Sample characteristics
We obtained GBM tissue samples from 70 patients, 45 men
(64%) and 25 women (36%) with a median age of 60 years (range,
16–81 years). All were diagnosed with primary GBM with a single
lesion, were treatment naı ¨ve, underwent surgery for maximal
resection and received standard external-beam radiotherapy (59.4
gray) with concomitant TMZ (single daily dose 75 mg/m2)
followed by monthly cycles of TMZ chemotherapy (daily dose
200 mg/m2 for five consecutive days)[3].
DNA for assessment of MGMT promoter methylation was
available from all 70 patients. MGMT immunohistochemistry
(IHC) was performed on 31 patients (Swedish cohort). RNA from
46 patients was available for assessment of MGMT gene
expression. Progression-free survival (PFS) data was available for
44 patients out of which 39 patients had at least one year follow-
up. Fourteen patients with less than 95% tumor resection were
excluded from PFS analysis and twelve patients were lost to follow-
up. The Venn diagram in Figure S1 shows how these different
measurements overlap in the patient cohorts.
Among the 44 patients with PFS data, the median PFS was 269
days (range, 71–766 days). PFS was not associated with gender but
did show a significant association with age where we observed a
median PFS of 314 days in younger patients vs 197 days in older
patients (HR =1.051, 95% CI [1.014–1.091], p=0.05,). Of note,
for the 24 patients in this group for whom IHC results were
available, patients with decreased MGMT protein expression
(immunonegative, IHC results #15%) had significantly better
PFS, 540 days vs 197 days, compared to patients with higher
MGMT protein expression (immunopositive, IHC results .15%)
(HR =8.85, 95% CI [2.179–35.714], p,0.0001) (Table 1 and
Figure S3). When patient samples were characterized as methylated
or unmethylated using the methylation profile of the entire
promoter (3R classification, see methods section and described
below) there was a strong association between methylation and PFS.
The median PFS for the methylated group was 540 days vs. 210
days for the unmethylated group (HR =5.23, 95% CI [2.089–
13.097], p,0.0001). The multivariate Cox proportional hazard
model showed MGMT IHC and 3R classification as independent
predictors of PFS (Table 1).
Stratification of methylation patterns into four major
groups
High resolution bisulfite sequencing of the entire CpG island in
70 GBM samples revealed highly heterogeneous methylation
Figure 2. Schematic of 3R classification. All three regions of the
MGMT promoter for each patient are classified as methylated (M) or
unmethylated (UM). Based on the status of these three regions, patients
are classified into four major groups: Group A) all regions unmethylated,
Group B) one region methylated, Group C) two regions methylated, and
Group D) all three regions methylated. For correlation analysis, Groups
B and C were further subdivided as indicated.
doi:10.1371/journal.pone.0016146.g002
Table 1. Sample characteristics and Kaplan-Meier analysis of
PFS.
Category Subcategory
Number of
Patients p-value
Age ,60 22 (50%) 0.05
$60 22 (50%)
Gender Male 28 (64%) 0.784
Female 16 (36%)
*IHC #15%
(Immunonegative)
14 (58%) ,0.0001
.15%
(Immunopositive)
10 (42%)
*3R M 17 (39%) ,0.0001
UM 27 (61%)
*The multivariate Cox proportional hazard model showed MGMT IHC and 3R
classification as independent predictors of PFS.
doi:10.1371/journal.pone.0016146.t001
coded rectangles. Absence of any of the shapes indicates results not available. All CpG sites belonging to the three regions, R1, R2 and R3 are shown
within the blue outlined squares. The four distinct groups are outlined with red squares. The qMSP region is labeled with qMSP primers in R3. The
transcription start site (TSS) of the MGMT gene is marked by an arrow.
doi:10.1371/journal.pone.0016146.g001
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of all 70 GBM samples identified three major sets of CpG site
clusters. Each set occupied a contiguous part of the CpG island
forming three distinct regions. The coordinates for each region are
measured from the transcription start site (TSS). Region 1 (R1)
coordinates are 2452 to 2317, Region 2 (R2) coordinates are
2302 to 2105, and Region 3 (R3) coordinates are 40 to 255. R1
and R2 are upstream of the TSS whereas R3 is downstream of the
TSS. As indicated in Figure 1, the previously reported MSP [26]
and qMSP region [8] is contained in R3. The primers used in the
commercial qMSP test cover seven CpG sites in R3.
Methylation profile classification based on these three regions
led to the identification of four methylation patterns: Group A, the
unmethylated group, consisting of samples with all three regions
unmethylated; Group B, the lightly methylated group, consisting
of samples with only one region methylated; Group C, the
moderately methylated group, consisting of samples with any two
regions methylated; and Group D, consisting of samples that were
densely methylated (Figure 1 and Figure 2).
Single site-based correlation analysis
Table S1 shows how well methylation at an individual CpG site
is correlated with MGMT mRNA expression (46 samples), protein
expression (31 samples) and PFS (44 samples). A total of 36
individual CpG sites from across the promoter were found to be
significantly correlated with MGMT mRNA expression. Of note,
six of these CpG sites are located in the region measured by the
qMSP test (Labcorp, USA)[8]. We found that fewer CpG sites, 25
total, were significantly correlated with MGMT protein expression
(p,0.05, Pearson’s chi-square test). The highest concordance
between an individual CpG site methylation and protein
expression was 71%. Four of the seven sites within the qMSP
test region were significantly correlated with protein expression. A
total of 17 CpG sites were found to be predictive of PFS. Two of
them were located in R1, seven in R2 and eight in R3. Only one of
the seven sites of the qMSP test (LabCorp, USA)[8] was
significantly correlated with PFS. Of note, seven CpG sites,
CpG 38, CpG 73, CpG 80, CpG 81, CpG 82, CpG 86 and CpG
89 (Table 2), were found to be significantly correlated across all
three variables: mRNA expression, protein expression and PFS.
Region-based correlation analysis
Methylation of any of the three major CpG cluster regions was
significantly correlated with mRNA expression (p,0.05). The
methylation status of regions R2 and R3, but not R1, showed
significant concordance with protein expression and PFS (Table 3).
When analyzed by groups, the largely unmethylated group A
consisted of a subset of samples with high mRNA expression
(student’s t test, p.0.05) and high protein expression (p=0.02)
when compared to Groups C and D. Twelve out of fourteen
patients had disease progression before one year (HR 5.23, 95%
CI [2.089–13.097], p,0.0001, median PFS of 540 days in Groups
C and D vs 210 days in Group A). In contrast, Group D, the
highly methylated group in which all three regions are methylated
compared to Groups A and B, had low mRNA expression
(student’s t test, p=0.036) and negative protein expression
(p=0.001). Six out of the 10 patients in this group had PFS
greater than one year (HR =3.312, 95% CI [1.192–9.201],
p=0.016, median PFS of 373 days in Group D vs 210 days in
Groups A and B).
Group B, the lightly methylated group consisting of samples
with one out of three regions methylated, was similar to Group A;
consisting of a subset of samples with high protein expression
(p=0.04) and high mRNA expression approaching statistical
significance (student’s t test, p=0.07). Nine out of nine patients
had disease progression before one year (HR =8.906, 95% CI
[2.244–35.343], p,0.0001, median PFS of 540 days in Groups C
and D vs 202 days in Group B). Group C, the moderately
methylated group consisting of samples with any two regions
methylated, was similar to Group D. The samples in this group
Table 2. Significant individual CpG site correlations with MGMT mRNA expression, MGMT protein expression and PFS.
CpG site
distance
from TSS %Meth Region mRNA (r)
Protein
(%concordance)
PFS (hazard ratio [95%
confidence interval])
8 2448 78 R1, MLPA-R1 20.159 61 1.881 [0.868–4.076]
22 2302 35 R2, MLPA-R2 2.407** 58 2.460 [1.066–5.674]*
38
# 2181 33 R2 2.371* 68** 2.463 [0.995–6.098]*
73
# 53 35 R3 2.362* 65** 3.084 [1.063–8.948]*
75 65 35 R3, qMSP 2.376** 68** 1.590 [0.678–3.73]
76 68 28 R3, qMSP 2.452** 58* 1.688 [0.687–4.151]
77 72 28 R3, qMSP 2.453** 58 2.153 [0.876–5.292]
78 82 26 R3, qMSP 2.384** 52 1.186 [0.483–2.916]
80
# 89 43 R3, MLPA-R3 2.408** 68* 2.311 [1.021–5.23]*
81
# 94 37 R3 2.292* 68* 2.539 [1.076–5.992]*
82
# 100 37 R3 2.321* 68** 2.508 [1.102–5.711]*
86
# 142 39 R3 2.399** 68* 2.903 [1.17–7.2]*
87 155 43 R3, qMSP 2.334* 68* 1.786 [0.793–4.025]
88 160 24 R3, qMSP 20.162 52 1.837 [0.638–5.289]
89
# 172 54 R3, qMSP 2.338* 71* 2.255 [1.071–4.748]*
r=Spearman’s rank correlation coefficient.
*p-value ,0.05.
**p-value ,0.01.
#These seven CpG sites are significantly correlated with all three measures: MGMT mRNA expression, protein expression and progression-free survival.
doi:10.1371/journal.pone.0016146.t002
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t test, p.0.05) and negative protein expression (p=0.006). Five
out of six patients had over one year progression-free-survival (HR
=10.002, 95% CI [2.214–45.179], p=0.003, median PFS of 753
days in Group C vs 210 days in Groups A and B). Subgroup
analysis of Groups B and C did not reveal any significant
difference in correlation with mRNA expression, protein expres-
sion or PFS within each subgroup compared with the parent
group.
We classified Group C and Group D samples as methylated and
Group A and B samples as unmethylated. This classification of
methylation patterns (3R classification) showed strong correlation
with mRNA expression and protein expression (Table 3 and Table
S2). The methylated group identified by the 3R classification also
correlated with longer PFS (Table 3, Figure 3A). Of note,
methylation patterns in the qMSP region failed to correlate with
progression-free survival in our cohort (Table 3, Figure 3B) but did
show correlation with mRNA expression and protein expression.
MS-MLPA
Analysis of the entire MGMT promoter suggested that a test
investigating methylation of individual CpG sites across the entire
promoter might be more informative than methods focused on a
single region. We recognize that bisulfite sequencing for 3R
classification is not feasible in the clinical setting as it is an
expensive and time consuming method that cannot be performed
on paraffin-fixed or archived tissue. To overcome these limitations,
we used an MS-MLPA based test [22] which can detect MGMT
methylation in all three promoter regions at the key CpG sites used
in the 3R classification. Three different MS-MLPA assays were
developed: 1) MLPA-R1 assessed CpG 8 methylation in region
R1, 2) MLPA-R2 assessed CpG 22 methylation in region R2, and
3) MLPA-R3 assessed CpG 80 methylation in region R3. We
obtained MS-MLPA results for all 70 patients for which bisulfite
sequencing data were available. We then classified samples with
two or more positive MS-MLPA probes into the methylated group
and assigned the rest into the unmethylated group. This MS-
MLPA based 3R classification showed high correlation with
mRNA expression, protein expression and progression-free
survival (p,0.01, see Table 3 and Figure 3C).
MS-MLPA and qMSP
Results of the commercially available qMSP test (Labcorp,
USA) [8] were available for 28 patients in the Swedish cohort. In
these 28 patients, the MS-MLPA based 3R classification test
identified 13 patients (46%) as having MGMT methylation
compared to only 8 (29%) patients identified by the qMSP test.
Kaplan-Meier analysis for PFS showed that MS-MLPA classifica-
tion successfully differentiated methylated patients with improved
PFS whereas the qMSP test had not yet achieved significance (see
Figure 4), with the caveat that the majority of these patients in this
small cohort had a follow-up of less than one year. We examined
three patients who were identified as unmethylated by qMSP but
methylated by MS-MLPA classification and had a follow-up of
more than one year. One of these patients had 314 days of
progression-free survival whereas the other two patients remain
progression-free at 380 and 766 days. Thus, in this small cohort of
28 patients, it is interesting to observe that MLPA classification
appears to be more sensitive in identifying patients with clinically
significant MGMT methylation who might otherwise be missed
using the qMSP test. These observations need to be confirmed in a
larger prospective study.
Discussion
In this study, we sought to further define the relationship
between MGMT promoter methylation, mRNA expression,
protein IHC and clinical response to therapy. We chose a uniform
patient population who shared the same diagnosis and underwent
similar treatment regimens. We used progression-free-survival as
the clinical outcome measure in order to avoid differences between
patients in response to post-progression treatment. This endpoint
has been recently validated by a study which showed that six-
month progression-free survival can be used as an alternative
primary efficacy endpoint to overall survival in newly diagnosed
glioblastoma patients receiving temozolomide [27]. We used
bisulfite sequencing, which is currently the most comprehensive
technology available to characterize methylation patterns across
the whole MGMT promoter, and, because it is quantitative,
allowed us to stratify patients in four major groups with varying
levels of methylation instead of using a binary classification.
In general, we observed that methylation profiles in GBM
patients are heterogeneous across the promoter region and also
within individual clones from the same tissue sample, most likely
representing the heterogeneity of cell types within the tumor
sample (Figure S2). Methylation of either upstream (R1, R2) or
downstream (R3) regions resulted in transcriptional repression and
decreased protein expression with the exception of one patient (in
subgroup C2) that showed 30% MGMT positive cells. Although
methylation of either of the downstream or upstream region was
sufficient for transcriptional repression, improved response to
treatment as measured by PFS was observed only for Group C and
Group D where a larger part of the promoter region was
methylated.
Table 3. Correlation of MGMT promoter methylation patterns with MGMT mRNA expression, MGMT protein expression and PFS.
Classification mRNA (r) Protein (%concordance) PFS (hazard ratio [95% confidence interval])
R1 2.382** 55 2.034 [0.964–4.29]
R2 2.373* 74** 2.275 [1.025–5.052]*
R3 2.321* 71** 2.710 [1.243–5.908]**
3R 2.424** 74** 5.230 [2.089–13.097]**
MLPA 2.545** 71** 3.076 [1.301–7.27]**
qMSP 2.459** 71** 1.707 [0.728–4.003]
r= Spearman’s rank correlation coefficient.
*p-value ,0.05.
**p-value ,0.01.
doi:10.1371/journal.pone.0016146.t003
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on MGMT transcription are consistent with those of an earlier
study in cell lines [14], in which MGMT transcription was shown
to be regulated by methylation of both upstream and downstream
promoter regions. In the cell lines, methylation of either the
upstream or downstream promoter down-regulated mRNA
expression with downstream methylation being almost as effective
as methylation of the entire promoter. In a recent study [12],
Everhard et al. also studied methylation across the entire promoter
region of 70 GBM patients and showed that the majority of CpG
sites correlated with mRNA expression. In that study, patients
were classified into three groups: methylated, unmethylated and
intermediate methylation. The unmethylated group had the
highest mRNA expression, intermediate group had lower
expression and the methylated group had the lowest. Both
upstream and downstream promoter regions appeared to have
an additive effect on mRNA expression. Our results confirm and
extend these findings to include correlation of methylation at
individual CpG sites to protein expression and progression free
survival. In addition, we show that the three individual CpG sites
(CpG 72, CpG 74 and CpG 78) identified by Everhard et al. as
most predictive of mRNA expression fail to correlate significantly
with PFS in our cohort.
MGMT methylation assessed by the qMSP test has been
consistently shown to predict response to the alkylating agent
TMZ, measured by either PFS or overall survival, in GBM
patients [13,28,29,30,31,32]. The question remains as to whether
there is any additional benefit, either in sensitivity or predictive
value, from measuring methylation in upstream promoter regions.
Methylation of the upstream MGMT promoter region has been
shown to repress transcription [12,14,33] but its value for the
purposes of patient prognosis has not yet been explored. In our
cohort, the downstream region qMSP
P methylation status,
although not significantly correlated with PFS, did show a lower
frequency of disease progression in the methylated group (45% vs
75% at 1-year follow-up). We suspect that this would trend toward
statistical significance with a larger patient population. Of note,
when the methylation status was determined using our 3R
method, the frequency of disease progression was 31% in the
methylated group vs. 91% in the unmethylated group, which
achieved statistical significance within the study cohort. These
results show for the first time that the upstream region is
potentially important in considering the design and development
of a clinical test to measure MGMT methylation.
The MGMT methylation patterns observed in this study
confirm that the downstream region interrogated by the qMSP
test is well chosen given the constraint that only one region is
assessed. But our data also suggest that a semi-quantitative test that
can measure methylation across the entire promoter and is not
dependent on co-methylation of multiple sites may be more
informative than qMSP and other MSP-based tests that measure
methylation only at the single downstream region and appear to
fail when the CpG sites spanning MSP primers are not densely
methylated (See Figure 2 – group C2). Unfortunately, bisulfite
sequencing is laborious, costly, and requires fresh frozen tissue,
which makes it an unrealistic method for routine diagnostics in the
Figure 3. 3R classification and MS-MLPA predict PFS in GBM.
Kaplan-Meier estimation of PFS according to MGMT promoter
methylation status determined using: A) 3R classification method -
The median PFS for the methylated group was 540 days vs. 210 days for
the unmethylated group (HR =5.23, 95% CI [2.089–13.097], p,0.0001),
B) qMSP
P - The median PFS for the methylated group was 373 days vs.
224 days for the unmethylated group (HR =1.707, 95% CI [0.728–4.003],
p=0.213), and C) MS-MLPA - The median PFS for the methylated group
was 540 days vs. 210 days for the unmethylated group (HR =3.076, 95%
CI [1.301–7.27], p=0.007).
doi:10.1371/journal.pone.0016146.g003
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individual CpG site methylation across the entire promoter region
and, as a PCR-based test, is more readily adapted to the clinical
setting. With that rationale, we utilized an MS-MLPA [22] test for
3R classification in which the three CpG sites interrogated by the
MS-MLPA probes are derived from the three different promoter
regions which are used for the 3R classification. Our MS-MLPA
based 3R classification showed excellent correlation to mRNA and
protein expression. The methylated group by MS-MLPA 3R
classification was highly associated with improved progression-free
survival (58% were progression-free at one year in the methylated
group vs. 22% in the unmethylated group). A comparison of the
MS-MLPA 3R test with the qMSP test (LabCorp, USA) [8] in a
28 patient cohort showed it was potentially more sensitive in
identifying methylated patients (46% methylated patients vs. 29%).
Our results suggest that further analysis in a larger independent
patient cohort would further define the potential advantages of a
whole promoter MS-MLPA based analysis.
There is an ongoing debate about whether MGMT IHC is a
good prognostic or predictive marker in GBM. Even though the
majority of studies have shown MGMT IHC does not correlate
with patient survival [24,29,30,34], Capper et al. showed that if
the test is done before radiation and chemotherapy, if evaluation is
done with special attention to the infiltration zone of diffuse
astrocytomas, and if glioma grade is taken into account for cutoff
values, then an IHC result of greater than 15% positively stained
nuclei can indeed predict survival in GBM patients [21]. All of the
large-scale studies to date [30,34,35] have failed to find any
concordance between MGMT IHC results and promoter
methylation as measured by the MSP test; although a couple of
small studies have shown concordance [36,37]. The observed
concordance between our MGMT IHC results and promoter
methylation status as defined by 3R classification might be
attributed to the fact that we are taking into consideration the
methylation status of the entire promoter which may be a better
predictor of protein expression than the MSP test which is
restricted to a small segment of Region 3. Of note, the
combination of IHC with the MSP test has been used to identify
a methylated-immunonegative group with a more positive
prognosis [30]. In our subset of patients in which IHC results
were available, we observed a strong correlation between the
immunopositive group and reduced PFS. A subset of patients,
those that had no MGMT protein expression despite the fact they
had no detectable promoter methylation, are of particular interest.
It is difficult to say whether the gene requires activation which may
be triggered by temozolomide treatment [38,39], the gene is
silenced by other mechanisms [40,41], or if it is due to tumor
heterogeneity [30,42]. This patient group with unmethylated-
immunonegative MGMT status has been shown to have the worst
prognosis [30]. In our study three out of four patients falling in this
group had less than one year PFS.
Our findings suggest that careful consideration should be given
to single CpG site evaluation in the development of clinical tests to
measure methylation given the degree of heterogeneity seen in
methylation patterns both within an individual patient and across
the patient population. A whole promoter method focused on key
single CpG site predictors of response to therapy might have an
advantage over semi-quantitative approaches focused on a single
region. We anticipate that further refinements in a MGMT
methylation test for use in clinical decision-making might include a
test similar to our MS-MLPA 3R classification method. Further
validation of this approach will require a prospective study to show
how methylation of the entire MGMT promoter region affects
MGMT mRNA and protein expression and whether it can
reliably improve upon current methodology to predict patient
response to therapy.
Supporting Information
Figure S1 Clinical measurements. This venn diagram
shows the overlap in our patient population of measurements of
MGMT mRNA, MGMT protein and progression-free survival.
Seventy patient samples were assessed for MGMT promoter
methylation. MGMT protein assessment was available for 31
patients. MGMT gene expression could be assessed for 46 of the
patients. Radiology reports for assessment of one year PFS were
available for 39 patients.
(DOC)
Figure S2 Clonal heterogeneity within an individual
tumor sample. Each line represents a single clone sequenced
from an individual patient’s tumor sample. Each circle represents
Figure 4. MS-MLPA predicts PFS in 28 GBM patients. Kaplan-
Meier estimation of PFS according to MGMT promoter methylation
status determined using: A. MS-MLPA (p-value =0.002) and B. qMSP
(p-value =0.089).
doi:10.1371/journal.pone.0016146.g004
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methylated. For an individual tumor sample, the fractional
methylation at a single CpG site is calculated by dividing the
number of positive methylated clones by the total number of
clones sequenced. In this patient, a total of 24 clones were
sequenced.
(DOC)
Figure S3 Age and MGMT protein predict PFS in GBM.
Kaplan-Meier estimation of PFS determined using: A) Age - The
median PFS in younger patients was 314 days vs 197 days in older
patients (HR =1.051, 95% CI [1.014–1.091], p=0.05). B)
Gender - The median PFS for the females was 224 days vs. 258
days for male patients (HR =0.902, 95% CI [0.432 – 1.885],
p=0.784), and C) MGMT protein (IHC) – The median PFS of
patients with decreased MGMT protein expression (immunone-
gative, IHC results #15%) was significantly better, 540 days vs
197 days, compared to patients with higher MGMT protein
expression (immunopositive, IHC results .15%) (HR =8.85,
95% CI [2.179–35.714], p,0.0001).
(DOC)
Table S1 Single site correlation.
(DOC)
Table S2 Correlation of MGMT promoter methylation
patterns with MGMT mRNA expression, MGMT protein
expression and PFS.
(DOC)
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